Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Copaxone patents confirmed as invalid

Executive Summary

Four patents protecting Teva’s Copaxone (glatiramer acetate) 40mg/ ml thrice-weekly formulation are invalid as obvious, the US Court of Appeals has confirmed in two parallel decisions. The decisions remove the threat of damages against Mylan and Sandoz, which launched glatiramer acetate (GA) 40mg pre-filled syringes ‘at risk’ pending Teva’s appeal (Generics bulletin, 16 February 2018, page 15).

You may also be interested in...



Pharmascience Appeals Canadian Copaxone 40mg Ruling

A mixed verdict in Canadian litigation involving Pharmascience has seen one patent protecting Teva’s Copaxone 40mg upheld and one deemed invalid. Pharmascience plans to appeal.

EPO Reversal Overturns Copaxone 40mg Patent

Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel